Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) [clinicaltrials:NCT00160082]
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) [clinicaltrials:NCT00160082]
Bio2RDF identifier
NCT00160082
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00160082
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The primary objective w ...... ability, balance and safety.
brief title [clinicaltrials_vocabulary:brief-title]
Efficacy and Safety of Xepol ( ...... With Post-Polio Syndrome (PPS)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2003-05-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Study Rationale:
...... ence and literature reviewed.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-09-09T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Intravenous Immunoglobuline
Late effects of polio
Late onset polio sequele
Paralylic Polio
Poliomyelitis
Post Polio Syndrome
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2007-04-02T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00160082
official title [clinicaltrials_vocabulary:official-title]
Efficacy and Safety of Xepol ( ...... ntre, Placebo Controlled Study
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
reference [clinicaltrials_vocabulary:reference]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2001-01-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2005-09-01T00:00:00Z
identifier
clinicaltrials:NCT00160082
title
Efficacy and Safety of Xepol ( ...... With Post-Polio Syndrome (PPS)
@en
type
label
Efficacy and Safety of Xepol ( ...... ) [clinicaltrials:NCT00160082]
@en